An investigation on behalf of investors in CombiMatrix Corp (NASDAQ:CBMX) shares over potential wrongdoing at CombiMatrix Corp was announced and NASDAQ:CBMX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/11/2017 -- An investigation on behalf of investors in shares of CombiMatrix Corp (NASDAQ:CBMX) was announced over potential breaches of fiduciary duties by certain officers and directors at CombiMatrix.
Investors who purchased shares of CombiMatrix Corp (NASDAQ:CBMX) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm concerns whether certain CombiMatrix Corp directors breached their fiduciary duties.
Irvine, CA based CombiMatrix Corporation is a provider of molecular diagnostic solutions that specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. CombiMatrix Corp reported that its annual Total Revenue rose from $10.09 million in 2015 to $12.87 million in 2016 and that its Net Loss declined from $6.60 million in 2015 to $4.14 million in 2016. Shares of CombiMatrix Corp (NASDAQ:CBMX) grew from $2.20 per share in November 2016 to as high as $6.40 per share on May 8, 2017.
On May 10, 2017, NASDAQ:CBMX shares closed at $6.05 per share.
Those who purchased shares of CombiMatrix Corp have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego